Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance (vol 24, pg 1, 2022)

被引：2

作者：

Flisiak, Robert ^{[1
]}

Zarebska-Michaluk, Dorota ^{[2
,3
]}

Rogalska, Magdalena ^{[1
]}

Krynska, Justyna Anna ^{[1
]}

Kowalska, Justyna ^{[4
]}

Dutkiewicz, Ewa ^{[5
,6
]}

Dobrowolska, Krystyna ^{[2
]}

Jaroszewicz, Jerzy ^{[7
]}

Moniuszko-Malinowska, Anna ^{[8
]}

Rorat, Marta ^{[9
]}

Podlasin, Regina ^{[10
]}

Tronina, Olga ^{[11
]}

Rzymski, Piotr ^{[12
]}

机构：

[1] Med Univ Bialystok, Dept Infect Dis & Hepatol, 15-540,Ul Zurawia 14, Bialystok, Poland

[2] Jan Kochanowski Univ Humanities & Sci, Dept Infect Dis, Kielce, Poland

[3] Prov Hosp, Kielce, Poland

[4] Med Univ Warsaw, Dept Adults Infect Dis, Warsaw, Poland

[5] ZOZ, Busko Zdroj, Poland

[6] Jan Kochanowski Univ Humanities & Sci, Coll Med, Kielce, Poland

[7] Med Univ Silesia, Dept Infect Dis & Hepatol, Katowice, Poland

[8] Med Univ Bialystok, Dept Infect Dis & Neuroinfect, Bialystok, Poland

[9] Wroclaw Med Univ, Dept Forens Med, Wroclaw, Poland

[10] Hosp Infect Dis, Dept 4, Warsaw, Poland

[11] Med Univ Warsaw, Dept Transplantat Med Nephrol & Internal Dis, Warsaw, Poland

[12] Poznan Univ Med Sci, Dept Environm Med, Poznan, Poland

来源：

PHARMACOLOGICAL REPORTS | 2022年 / 74卷 / 06期

关键词：

COVID-19; Molnupiravir; Omicron; Real-world experience; SARS-CoV-2; Treatment;

D O I：

10.1007/s43440-022-00419-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections. Methods: Among 11,822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 30 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons. Results: Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups. Conclusions: The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age. © 2022, The Author(s).

引用

页码：1328 / 1328

页数：1